Role of Ivabradine in Patients with Heart Failure with Preserved Ejection Fraction

Nadeem, Muhammad; Hassib, Mohab; Aslam, Hafiz Muhammad; Fatima, Dania; Illahi, Yasir

doi:10.7759/cureus.7123

Cited by 3 publications

(1 citation statement)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This implies that the cardiac output depends to a greater extent on the heart rate (heart rate × stroke volume = cardiac output). Therefore, heart rate reduction with ivabradine in this context would be detrimental [ 134 ]. Furthermore, ivabradine failed to improve E / e ’ and reduce NT-proBNP concentration in the EDIFY trial [ 131 ].…”

Section: Emerging Drug Therapies For Hfpefmentioning

confidence: 99%

Drug Therapy for Acute and Chronic Heart Failure with Preserved Ejection Fraction with Hypertension: A State-of-the-Art Review

Hiraiwa,

Okumura,

Murohara

2024

Am J Cardiovasc Drugs

View full text Add to dashboard Cite

In this comprehensive state-of-the-art review, we provide an evidence-based analysis of current drug therapies for patients with heart failure with preserved ejection fraction (HFpEF) in the acute and chronic phases with concurrent hypertension. Additionally, we explore the latest developments and emerging evidence on the efficacy, safety, and clinical outcomes of common and novel drug treatments in the management of HFpEF with concurrent hypertension. During the acute phase of HFpEF, intravenous diuretics, mineralocorticoid receptor antagonists (MRAs), and vasodilators are pivotal, while in the chronic phase, angiotensin-converting enzyme inhibitors and angiotensin receptor blockers have proven effective in enhancing clinical outcomes. However, the use of calcium channel blockers in HFpEF with hypertension should be approached with caution, owing to their potential negative inotropic effects. We also explored emerging drug therapies for HFpEF, such as sodium–glucose co-transporter 2 (SGLT2) inhibitors, angiotensin receptor–neprilysin inhibitor (ARNI), soluble guanylate cyclase (sGC) stimulators, novel MRAs, and ivabradine. Notably, SGLT2 inhibitors have shown promise in reducing heart failure hospitalizations and cardiovascular mortality in patients with HFpEF, regardless of their diabetic status. Additionally, ARNI and sGC stimulators have demonstrated potential in improving symptoms, functional capacity, and quality of life. Nonetheless, additional research is necessary to pinpoint optimal treatment strategies for HFpEF with concurrent hypertension. Furthermore, long-term studies are essential to assess the durability and sustained benefits of emerging drug therapies. Identification of novel targets and mechanisms underlying HFpEF pathophysiology will pave the way for innovative drug development approaches in the management of HFpEF with concurrent hypertension.

show abstract

Section: Emerging Drug Therapies For Hfpefmentioning

confidence: 99%